<DOC>
	<DOCNO>NCT02401685</DOCNO>
	<brief_summary>POSNOC pragmatic , randomise , multicentre , non-inferiority trial . Aim For woman early stage breast cancer one two sentinel node macrometastases , ass whether adjuvant therapy alone worse adjuvant therapy plus axillary treatment , term axillary recurrence within 5 year . Stratification : Institution , Age ( &lt; 50 , ≥50 ) , Breast-conserving surgery ( BCS ) mastectomy , Estrogen receptor ( ER ) status ( positive , negative ) , Number positive node ( 1 , 2 ) , Intra-operative sentinel assessment use OSNA ( yes , ) . Interventions The study compare adjuvant therapy alone adjuvant therapy plus axillary treatment ( axillary node clearance ( ANC ) axillary radiotherapy ( ART ) ) . Sample Size : 1900 participant Follow-up : Participants follow 5 year . Adjuvant Therapy : All participant receive adjuvant systemic therapy ( chemotherapy and/or endocrine therapy ) . All participant may receive breast/chest wall radiotherapy . Axillary supraclavicular fossa radiotherapy allow randomised adjuvant therapy alone .</brief_summary>
	<brief_title>POSNOC - A Trial Looking Axillary Treatment Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Unifocal multifocal invasive tumour lesion ≤5 cm large dimension , measure pathologically woman randomise intraoperatively large tumour diameter mammogram ultrasound ( tumour size base single large tumour ; add size together multiple focus ) At sentinel node biopsy 1 2 sentinel nodes macrometastases ( tumour deposit &gt; 2.0mm large dimension define macrometastasis molecular assay ) Fit axillary treatment adjuvant therapy Have give write informed consent bilateral breast cancer 2 node macrometastases neoadjuvant therapy breast cancer previous axillary surgery body side schedule sentinel node biopsy receive adjuvant systemic therapy previous cancer le 5 year previously concomitant malignancy except adequately treat basal squamous cell carcinoma skin adequately treat situ carcinoma cervix adequately treat situ melanoma contra ipsilateral situ breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>sentinel lymph node biopsy</keyword>
	<keyword>axillary lymph node clearance</keyword>
	<keyword>axillary lymph node dissection</keyword>
	<keyword>macrometastases</keyword>
	<keyword>axillary radiotherapy</keyword>
	<keyword>POSNOC</keyword>
</DOC>